InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
9
Disclosed sells
4
T+90 hit rate
67%
T+90 mean return
+32.4%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by BERGER FRANKLIN M, Directeur Juridique. Officer active across 5 companies, notably Kezar Life Sciences, Inc.. Aggregated, 19 reports have been recorded. Breakdown: 9 buys · 4 sells. Total volume traded: €2.7m. Activity tracked since 21 September 2021. The latest transaction was disclosed on 20 June 2025 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations19 total
29,600 sharesCommon StockSEC:0001193125-26-279726:0
29,600 shares0Common StockSEC:0000950170-25-089606:0
15,000 shares@ US$3.19233.7% of flowCommon StockSEC:0000950170-25-006489:0
Ideal exit: 12 Oct 2025 (T+270)
15,000 shares@ US$3.19233.7% of flowCommon StockSEC:0000950170-25-006589:0
Ideal exit: 12 Oct 2025 (T+270)
359,606 shares@ US$2.846176.2% of flowCommon StockSEC:0000950170-24-135930:0
33,150 shares0Common StockSEC:0000950170-24-074987:0
1,005,207 sharesCommon Stock, par value $0.001 per shareSEC:0001999371-24-000962:0
23,259 shares@ US$5.7324.6% of flowCommon SharesSEC:0000950170-23-065921:0
Ideal exit: 17 Aug 2024 (T+270)
60,000 shares@ US$5.3561.2% of flowCommon StockSEC:0000950170-23-064584:0
Ideal exit: 29 Jul 2024 (T+270)
25,000 shares@ US$3.0014.2% of flowCommon SharesSEC:0000899243-23-000914:0
45,000 shares@ US$7.8049.8% of flowCommon StockSEC:0001104659-22-121849:0
Ideal exit: 18 Aug 2023 (T+270)
25,500 shares@ US$5.150310.1% of flowCommon StockSEC:0000899243-22-035942:0
16,166 shares@ US$5.1566.3% of flowCommon StockSEC:0000899243-22-035942:1
42,881 shares@ US$5.8336.6% of flowCommon StockSEC:0000899243-22-035691:0
Ideal exit: 5 Aug 2023 (T+270)
15,000 shares@ US$15.960.40% mcap70.6% of flowCommon StockSEC:0001209191-22-020584:0
Ideal exit: 13 Dec 2022 (T+270)
3,786 shares@ US$14.300.32% mcap50.0% of flowCommon StockSEC:0000899243-21-037351:0
Ideal exit: 18 Jun 2022 (T+270)
8,896 shares@ US$5.910.083% mcap14.7% of flowCommon StockSEC:0001209191-21-057418:0
8,896 shares@ US$5.9114.7% of flowCommon StockSEC:0001209191-21-057418
3,786 shares@ US$14.306.8% of flowCommon StockSEC:0000899243-21-037351
Ideal exit: 18 Jun 2022 (T+270)
19 of 19 declarations
About BERGER FRANKLIN M
Zoran Zdraveski is Chief Legal Officer at TScan Therapeutics, Inc. He is responsible for managing legal affairs and regulatory compliance. His role is essential in protecting the company's interests and ensuring adherence to applicable laws and regulations.
